CURRICULUM VITAE Biographical Information Name: Zachary Simmons, M.D. Address: Penn State Milton S. Hershey Medical Center Department of Neurology – EC037 30 Hope Drive, PO Box 859 Hershey, PA 17033 Telephone: (717) 531-1802 Fax: (717) 531-0384 E-mail: [email protected]Education 1978 Dartmouth College, Hanover, New Hampshire, B.A. (Summa Cum Laude, Highest Distinction in Biochemistry) 1982 University of Florida College of Medicine, Gainesville, Florida, M.D. (With Honors) Postgraduate Training 1982-1983 Resident in Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa 1983-1986 Resident in Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa 1990-1992 Fellow in EMG and Neuromuscular Diseases, Departments of Neurology and Physical Medicine and Rehabilitation, University of Michigan Medical Center, Ann Arbor, Michigan Academic Appointments 1990-1992 Lecturer in Neurology, University of Michigan Medical School, Ann Arbor, MI 1992-1997 Assistant Professor of Medicine, Division of Neurology, Penn State College of Medicine, Hershey, PA 1997-2002 Associate Professor of Medicine, Division of Neurology, Penn State College of Medicine, Hershey, PA 1997- Member, Graduate School Faculty, Penn State University, State College, Pennsylvania 2003-2004 Interim Chair, Department of Neurology, Penn State College of Medicine, Hershey, PA 2002- Professor, Department of Neurology (formerly Division of Neurology), Penn State College of Medicine, Hershey, PA 2009- Research Professor, Department of Psychology, Philadelphia College of Osteopathic Medicine, Philadelphia, PA 2011- Professor, Department of Humanities, Penn State College of Medicine, Hershey, PA Administrative Appointments 1986-1988 General Neurology Private Practice, Ithaca, NY 1988-1990 General Neurology Private Practice, Greenbelt, MD 1992- Director, Neuromuscular Program, Penn State Milton S. Hershey Medical Center
Transcript
CURRICULUM VITAE
Biographical Information
Name: Zachary Simmons, M.D.
Address: Penn State Milton S. Hershey Medical Center Department of Neurology – EC037 30 Hope Drive, PO Box 859
1978 Dartmouth College, Hanover, New Hampshire, B.A. (Summa Cum Laude, Highest Distinction in Biochemistry)
1982 University of Florida College of Medicine, Gainesville, Florida, M.D. (With Honors) Postgraduate Training
1982-1983 Resident in Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa
1983-1986 Resident in Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
1990-1992 Fellow in EMG and Neuromuscular Diseases, Departments of Neurology and Physical Medicine and Rehabilitation, University of Michigan Medical Center, Ann Arbor, Michigan
Academic Appointments
1990-1992 Lecturer in Neurology, University of Michigan Medical School, Ann Arbor, MI 1992-1997 Assistant Professor of Medicine, Division of Neurology, Penn State College of Medicine,
Hershey, PA 1997-2002 Associate Professor of Medicine, Division of Neurology, Penn State College of
Medicine, Hershey, PA 1997- Member, Graduate School Faculty, Penn State University, State College, Pennsylvania
2003-2004 Interim Chair, Department of Neurology, Penn State College of Medicine, Hershey, PA 2002- Professor, Department of Neurology (formerly Division of Neurology), Penn State
College of Medicine, Hershey, PA 2009- Research Professor, Department of Psychology, Philadelphia College of Osteopathic
Medicine, Philadelphia, PA 2011- Professor, Department of Humanities, Penn State College of Medicine, Hershey, PA
Administrative Appointments 1986-1988 General Neurology Private Practice, Ithaca, NY
1988-1990 General Neurology Private Practice, Greenbelt, MD 1992- Director, Neuromuscular Program, Penn State Milton S. Hershey Medical Center
2
1996-2003 Director, Clinical Neurophysiology Training Program, Penn State Milton S. Hershey Medical Center, Hershey, PA
1992- Medical Director, Clinical Neurophysiology Laboratory and Neuromuscular Program, Penn State Milton S. Hershey Medical Center, Hershey, PA
1993-2012 Director, Muscular Dystrophy Association Clinic, Penn State Milton S. Hershey Medical Center, Hershey, PA
1995- Director, Amyotrophic Lateral Sclerosis Center, Penn State Milton S. Hershey Medical Center, Hershey, PA
2006-2009 Director, ALS Clinic, John P. Murtha Neuroscience and Pain Institute, Johnstown, PA. Membership in Professional Societies
American Academy of Neurology (Fellow) American Association of Electrodiagnostic Medicine (Fellow) American Neurological Association World Muscle Society Peripheral Nerve Society Licensure and Certification 1989 Board Certification, American Board of Psychiatry and Neurology #31681
1989 Board Certification, American Board of Electrodiagnostic Medicine #0809 1992 Pennsylvania Medical License #MD-046572-L
1994 Board Certification, American Board of Psychiatry and Neurology: Added Qualifications in Clinical Neurophysiology, #0450. Recertification 2004-2014.
Committees and Administrative Services: Penn State University and Hershey Medical Center 1994-1998 Member, Rehabilitation Council
1998 Member, Committee for the Development of Guidelines for Treatment of Painful Diabetic Neuropathy
2004- Member, Department of Neurology Promotion and Tenure Committee 2005- Member, Department of Neurosurgery Promotion and Tenure Committee
2005-2006 Member, Department of Neurology Steering Committee 2006- Member, Penn State Hershey Medical Center Ethics Committee, including Brain Death
Subcommittee. Chair of membership subcommittee effective 2008. Committees and Administrative Services: Regional and National
1992-1994 Member, Training Program Committee, American Association of Electrodiagnostic Medicine 1993-2000 Training Program Liaison, American Association of Electrodiagnostic Medicine
3
1994- Examiner, American Board of Electrodiagnostic Medicine 1994-1996 Member, Workshop Committee, American Association of Electrodiagnostic Medicine
1996- Member, Advisory Board, ALS Association, Greater Philadelphia Chapter 1998-2003 Member, Program Committee, American Association of Electrodiagnostic Medicine
1998- Member, ALS Center Directors Group 2000-2001 Member, ALS Peer Workgroup on Excellence in End of Life Care
2000-2004 Member and Chair, Maintenance of Certification Committee, American Board of Electrodiagnostic Medicine
2001- Member, Medical/Scientific Advisory Board, Myasthenia Gravis Foundation of America 2003-2004 Member, Professional Practice Committee, American Association of Electrodiagnostic Medicine
2004-2012 Chair, Publication Committee, ALS Research Group 2004- Member and site Primary Investigator, North East ALS Consortium
2004-2006 Member, Program Committee, American Association of Electrodiagnostic Medicine 2004-2006 Member, Examination Committee, American Board of Electrodiagnostic Medicine
2006-2012 Chair, Examination Committee, American Board of Electrodiagnostic Medicine 2006-2007 Member, Strategic Planning Committee, ALS Association
2008- Member, ALS Association Medical Advisory Group 2012- Member Board of Directors, American Association of Neuromuscular and Electrodiagnostic
Medicine
Teaching Activities: Pennsylvania State University and Hershey Medical Center Yearly Teaching Responsibilities - Students
• College of Medicine students, year 2: Ethics and Professionalism:
• Facilitator and evaluator for weekly small group sessions
• One yearly lecture on ALS during session on Advance Care Planning
• College of Medicine, year 3: MCLKS 704: Improving Health Care:
• Lecture on Delivering Bad News
• College of Medicine, year 4: Humanities 741: Education in Palliative and End of Life Care. Two lectures:
• Communicating Bad News
• Withholding/Withdrawing Therapy
• Biological Basis of Human Health and Disease (CMBIO 506 - PhD and MD/PhD): 1 lecture yearly Material Written for Student Courses
4
• “Painless Arm Weakness in a 55-Year-Old Woman.” Original Case for Problem-based learning, Neural & Behavioral Science Block. Co-authored with Stacey L. Clardy, PhD.
• Lecture Series for Clinical Neurophysiology and Neuromuscular Medicine fellows – 4 lectures yearly. Regular Neurology Resident Teaching Conferences
• Muscle and Nerve Biopsy Review Conference (twice per month) Student Mentoring/Preceptorships
• Preceptor, MD/PhD Clinical Exposure Program o 2003-2004: Stacey Grab
o 2004-2005: Meredith Hannan o 2005-2006: Meredith Hannan, Ryan Mitchell
o 2012: Xiaowei (Bill) Su
• Elements of Neuroscience: Clinical exposure of Neuroscience graduate students o 2006-2007: Colleen Henry
o 2009: BMS 597A Clinical rotation – Fatima Ali-Rahmani
• Graduate Student Clinical Rotation, Center for Neural Engineering, University Park
o 2012: BMS 571 Andrew Geronimo
• Medical Student Research o Summer 2004: Jennifer Hespell
o Summer-Fall 2010: § Julia Cupp: A longitudinal study of psychological morbidity in amyotrophic lateral
sclerosis § Kristen Zamietra: A study of the relationship between gastrostomy tube placement,
noninvasive ventilatory support, and quality of life in patients with amyotrophic lateral sclerosis
o Summer 2011-Summer 2012: § Elyse Smolcic: Identification and characterization of recommendations made in ALS
clinic § Timothy Fullam: Compliance with recommendations made in ALS clinic
o Summer-2012-Summer 2013: § Joshua Davies: An investigation of bulbar symptom management in patient with ALS
Dissertation and Thesis Committees
5
1999 Member, Doctoral Dissertation Committee, Heecheon You, Department of Industrial and Manufacturing Engineering, The Pennsylvania State University Graduate School: “The development of a risk assessment model for carpal tunnel syndrome.”
2001 Member, Master’s Thesis Committee, Raghu Kolluri, Graduate Program in Physiology, The Pennsylvania State University: “Acute quadriplegic myopathy and loss of myosin in ICU patients: cellular and molecular insight from a porcine model.”
2003-2004 Member, Doctoral Dissertation Committee, Jessica Allen, Department of Psychology, Philadelphia College of Osteopathic Medicine: “Caregivers’ relationship satisfaction and perception of competency as predictors of quality of life for ALS patients.”
2005- Member, Doctoral Dissertation Committee, Beatrice Chakroborty, Department of Psychology, Philadelphia College of Osteopathic Medicine: “Resiliency factors: predictors of quality of life and psychological hardiness in spousal caregivers of patients with amyotrophic lateral sclerosis.”
2006-2007 Member, Doctoral Dissertation Committee, Krista Olex, Department of Psychology, Philadelphia College of Osteopathic Medicine: “Caregiving in amyotrophic lateral sclerosis: a proposed investigation of coping mechanisms and grief processes.”
2006-2007 Member, Doctoral Dissertation Committee, Diana McNeil, Department of Psychology, Philadelphia College of Osteopathic Medicine: “A qualitative study of health outcomes of spousal caregivers of patients diagnosed with amyotrophic lateral sclerosis.”
2006-2007 Member, Doctoral Dissertation Committee, Jason Duff, Department of Psychology, Philadelphia College of Osteopathic Medicine: “Does verbal communication impairment affect quality of life in amyotrophic lateral sclerosis patients?”
2006-2008 Member, Doctoral Committee, Ryan Mitchell, Penn State University (trainee of Dr. James Connor).
2007-2008 Member, Doctoral Committee, Melissa Horowitz, Department of Psychology, Philadelphia College of Osteopathic Medicine: “Does social problem solving moderate the relationship between physical functioning and depression in ALS patients?”
2007-2009 Member, Doctoral Committee, Colleen Henry, Penn State University (trainee of Dr. Robert Levenson).
2008-2009 Member, Master’s Committee, Nicholas Wiley, Penn State University (trainee of Dr. James Connor). “Targeted Liposomes for Treatment of ALS in Mutant SOD1-G93A Mouse Model.”
2008-2009 Member, Doctoral Committee, Jenna Jebitsch, Department of Psychology, Philadelphia College of Osteopathic Medicine: “The Effect of Oral Communication Ability on the Spirituality and Religiosity of Individuals Diagnosed with Amyotrophic Lateral Sclerosis.”
2008-2009 Member, Doctoral Committee, Andrea Weller, Department of Psychology, Philadelphia College of Osteopathic Medicine: “Caregiver religiosity, spirituality, and positive emotion as predictors of psychological well-being and social satisfaction in ALS patients.”
2009-2010 Member, Doctoral Committee, Jamie Rodriquez, Department of Psychology, Philadelphia College of Osteopathic Medicine: “Understanding the Impact of Physical Functioning on the Experience, Desire, and Satisfaction of Physical, Emotional and Social Intimacies in Persons with Amyotrophic Lateral Sclerosis (ALS).”
6
2009-2010 Member, Doctoral Committee, Colleen Frey, Penn State University: “A Novel Interaction Between the A2A Adenosine Receptor and RAN Binding Protein 9 (RBP9) and the Role of RBP9 in GPCR Function.”
2009-2011 Member, Doctoral Committee, Jared Young, Department of Psychology, Philadelphia College of Osteopathic Medicine: “A National Study of Amyotrophic Lateral Sclerosis Multidisciplinary Clinic Utilization.”
209-2011 Member, Doctoral Committee, Kristen Labin, Department of Psychology, Philadelphia College of Osteopathic Medicine: “Social Problem Solving and Factors that Contribute to the Desire to Hasten Death Among ALS Patients.”
2009-2012 Member, Doctoral Committee, Fatima Ali-Rahmani, Penn State University.
2009-2012 Member, Doctoral Committee, Wint Nandar, Penn State University: “H63D HFE gene variant and neurodegenerative diseases.”
2012- Member, Doctoral Committee, Xiaowei Su, Penn State University.
Neuromuscular or Neurophysiology Fellowship Trainees 1994-1995 Sanjeevi Tivakaran, MD
1996-1997 Raymond Reichwein, MD 1997-1998 Ziad Mahadeen, MD
1998-1999 Jason Stabley, DO 1999-2000 Timothy Sullivan, MD
2002-2003 B. Lee Peterlin, DO 2003-2004 Kevin Scott, MD
2005-2006 Justin Fisher, MD; Gary Thomas, MD 2006-2007 Daniel Chehebar, MD; Mamta Verma, MD
Ad Hoc Reviewer Annals of Neurology American Journal of Physical Medicine and Rehabilitation Archives of Physical Medicine and Rehabilitation Diabetes Care European Journal of Neurology Expert Review of Neurotherapeutics Journal of Clinical Neuromuscular Disease Muscle & Nerve Neurology Neurology Network Commentary Quality of Life Research Invited Presentations
11/11/92 Parkinson’s Disease and Alzheimer’s Disease Berwick Hospital, Berwick, PA 4/14/93 Acute and Chronic Demyelinating
Polyneuropathy: Evaluation and Treatment Central Pennsylvania Neurological Society
MDA Conference, Grantville, PA 4/19/93 New Research in Muscular Dystrophy and ALS International Association of Firefighters
MDA Conference, Grantville, PA 11/8/93 Acute and Chronic Demyelinating
Polyneuropathy: Evaluation and Treatment Department of Neurology Conference,
Geisinger Medical Center, Bloomsburg, PA 2/15/94 Approach to Polyneuropathy Polyclinic Medical Center Grand Rounds
Polyclinic Medical Center, Harrisburg, PA 3/7/94 CIDP and Guillain-Barré Syndrome Allentown Area Neurologists, Allentown
Hilton, Allentown, PA 3/11/94 Guillain-Barré Syndrome and Other
Demyelinating Polyneuropathies American Association of Neuroscience Nurses
Hershey, PA 3/29/94 Chronic Inflammatory Demyelinating
Polyradiculoneuropathy Penn State – Lehigh Valley Neurology
Conference, Plymouth Meeting, PA 7/6/94 Immunotherapy of Neuromuscular Diseases Central Pennsylvania Neurological Society
8
Hershey, PA 10/11/94 Neuromuscular Diseases Department of Occupational Therapy
Elizabethtown College, Elizabethtown, PA 10/14/94 Outpatient Approach to Neuromuscular Disease Neuroscience Symposium
Lehigh Valley Hospital, Allentown, PA 3/22/95 Intravenous Immunoglobulin in the Treatment
of Neuromuscular Diseases Quantum Health Resources, Holiday Inn
Grantville, PA 10/20/95 ALS: An Overview ALS Workshop
Harrisburg Area Community College Harrisburg, PA
11/17/95 Parkinson’s Disease, Other Movement and Dementia
Central Pennsylvania Psychiatric Society Harrisburg, PA
11/21/95 MDA-Sponsored Research Muscular Dystrophy Association Support Group, Harrisburg, PA
6/21/96 Neuromuscular Disease and Respiratory Dysfunction
Pennsylvania Society for Respiratory care Camp Hill, PA
9/8/96 Myotrophin in the Treatment of ALS ALS Support Group, Hershey Medical Center, Hershey, PA
10/17/96 Update on ALS Central Pennsylvania Neurological Society, Hershey, PA
1/28/97 Congenital Myasthenic Syndromes Penn State – Lehigh Valley Neurology Conference, Shartlesville, PA
3/6/97 Diabetic Neuropathy Polyclinic Hospital, Harrisburg, PA 9/19/97 Workshop on Motor Unit Number Estimation American Association of Electrodiagnostic
Medicine Annual Meeting, San Diego, CA 10/3/97 Amyotrophic Lateral Sclerosis Department of Medicine Grand Rounds
Geisinger Medical Center, Danville, PA 1/7/98 Evaluation of Peripheral Neuropathy General Internal Medicine Faculty Conference,
Hershey Medical Center, Hershey, PA 3/20/98 Entrapment Neuropathies Williamsport Hospital Visiting Professor Program,
Williamsport, PA 9/18/98 ALS: Overview and Symptom Management ALS Association Symposium on Managing ALS,
Pittston Township, PA 9/17/99 ALS: Medical Update and Symptom
Management ALS Association Symposium on Managing ALS,
Reading, PA 9/22/99 Chronic Acquired Demyelinating Peripheral
Neuropathies Department of Neurology, University of Iowa,
Iowa City, IA 10/7/99 Workshop on Motor Unit Number Estimations American Association of Electrodiagnostic
9
Medicine Annual Meeting, Vancouver, BC 10/9/99 Reproducibility of Motor Unit Number
Estimation in Individual Subjects American College of Osteopathic Neurologists
Neurologists and Psychiatrist Annual Meeting 1/20/00 Localized Hypertrophy Neuropathy Penn State – Lehigh Valley Neurology
Conference, Shartlesville, PA 3/24/00 Amyotrophic Lateral Sclerosis (ALS): Current
Concepts in Clinical Management American Association of Neuroscience Nurses
Annual Meeting, Hershey, PA 5/6/00 Variants of Guillain-Barré Syndrome American Academy of Neurology Annual
Meeting, San Diego, CA 9/15/00-9/16/00
Immunotherapy in Neuromuscular Diseases American Association of Electrodiagnostic Medicine Annual Meeting, Philadelphia, PA
9/29/00 Case Studies in Peripheral Neuropathy General Internal Medicine Faculty Conference Hershey Medical Center, Hershey, PA
12/1/00 Muscle Pain, Fatigue, Fasciculations, and HyperCKemia
Medical Staff Meeting Research Medical Center, Kansas City, MO
12/2/00 Myasthenia Gravis: Review and Update Myasthenia Gravis Association, Kansas City, MO
1/21/01 Myasthenia Gravis: Review and Update Myasthenia Gravis Foundation of America Hershey Medical Center, Hershey, PA
1/31/01 Muscle Pain, Fatigue, Fasciculations and HyperCKemia
Visiting Professor, Department of Neurology University of Michigan
4/7/01 Peripheral Neuropathy 101: How Neurologists Classify and Evaluate Peripheral Neuropathies
Peripheral Neuropathy Symposium Lehigh Valley Hospital, Allentown, PA
5/6/01 Chronic Inflammatory Neuropathies American Academy of Neurology Annual Meeting, Philadelphia, PA
5/7/01 A Case of Lifelong Weakness: In Unusual Diagnostic and Management Problems in Neuromuscular Disease
American Academy of Neurology Annual Meeting, Philadelphia, PA
5/11/01 Variants of Guillain-Barré Syndrome American Academy of Neurology Annual Meeting, Philadelphia, PA
9/21/01 ALS: Medical Update and Symptom Management
Symposium on Managing ALS ALS Association, Wilkes-Barre, PA
10/4/01 Introduction to Immunotherapy American Association of Electrodiagnostic Medicine Annual Meeting, Albuquerque, NM
10/6/01 Amyotrophic Lateral Sclerosis American Association of Electrodiagnostic Medicine, Albuquerque, NM
3/22/02 Quality of Life in ALS ALS Association Research Symposium, Philadelphia, PA
10
4/15/02 Variants of Guillain-Barré Syndrome American Academy of Neurology Annual Meeting, Philadelphia, PA
4/15/02 A Case of Lifelong Weakness: In Unusual Diagnostic and Management Problems in Neuromuscular Disease
American Academy of Neurology Annual Meeting, Philadelphia, PA
4/19/02 Chronic Inflammatory Neuropathies American Academy of Neurology Annual Meeting, Philadelphia, PA
9/20/02 ALS Update and Symptom Management Symposium on Managing ALS ALS Association, Wilkes-Barre, PA
9/25/02 Demyelinating Polyneuropathies Peripheral Neuropathy Course, Stony Brook University, Long Island, NY
9/25/02 Neuropathies Associated With Connective Tissue Disease
Peripheral Neuropathy Course, Stony Brook University, Long Island, NY
10/11/02 Amyotrophic Lateral Sclerosis American Association of Electrodiagnostic Medicine, Toronto, Ontario, Canada
10/12/02 Amyotrophic Lateral Sclerosis American Association of Electrodiagnostic Medicine, Toronto, Ontario, Canada
11/15/02 Neuropathy in the Elderly Geriatric Grand Rounds, Penn State Hershey Medical Center, Hershey, PA
5/19/03 ALS: Overview and Research Update ALS Symposium, Harrisburg, PA
Internal Medicine Board Review Course, Hershey Medical Center, Hershey, PA
9/5/03 ALS Update Department of Neurology Grand Rounds, Penn State University, Hershey, PA
9/17/03 Amyotrophic Lateral Sclerosis American Association of Electrodiagnostic Medicine, San Francisco, CA
9/18/03 Immunotherapy in Neuromuscular Diseases American Association of Electrodiagnostic Medicine Annual Meeting, San Francisco, CA
11/7/03 Quality of Life in ALS ALS Research Symposium, Hershey, PA
4/26/04 A Case of Lower Extremity Weakness: In Unusual Diagnostic and Management Problems in Neuromuscular Disease
American Academy of Neurology Annual Meeting, San Francisco, CA
9/19/04 Quality of Life in Amyotrophic Lateral Sclerosis
15th International Conference on Care of the Terminally Ill, Montreal, Quebec, Canada
10/22/04 ALS Research at Penn State Hershey Medical Center: Overview and Future Plans
ALS Research Symposium, Hershey, PA
11/4/04 Workshop on Quantitative Sensory Testing American Association of Electrodiagnostic
11
Medicine, Savannah, GA
11/6/04 Amyotrophic Lateral Sclerosis American Association of Electrodiagnostic Medicine, Savannah, GA
12/2/04 Key Determinants of Quality of Life in ALS 15th International Symposium on ALS/MND, Philadelphia, PA
2/16/05 Neurology Pennsylvania Youth Apprenticeship Program, Hershey, PA
2/18/05 ALS Update Department of Neurology Grand Rounds, Penn State University, Hershey, PA
5/14/05 Motor Neuron Disease Neuromuscular Disease Symposium, Lehigh Valley Hospital, Allentown, PA
9/8/05 Measuring Quality of Life in ALS 4th Annual Meeting, North East ALS Consortium, Boston, MA
9/24/05 Amyotrophic Lateral Sclerosis American Association of Electrodiagnostic Medicine, Monterey, CA
10/21/05 Oxidative Stress/Drug Delivery in ALS 3rd Annual ALS Research Symposium, Hershey, PA
10/21/05 Measuring Quality of Life in Individuals with ALS
3rd Annual ALS Research Symposium, Hershey, PA
2/10/06 ALS: New Concepts About an Old Disease Department of Neurology Grand Rounds, Penn State University, Hershey, PA
9/8/06 A Multicenter Validation Study of a New ALS Quality of Life Instrument
5th Annual Meeting, North East ALS Consortium, Boston, MA
10/14/06 MRI: A New Way to Look at ALS American Association of Neuromuscular and Electrodiagnostic Medicine, Washington, DC
10/20/06 MRI and Cognitive Assessments in ALS: New Ways to Study an Old Disease
ALS Research Update, ALS Association Greater Phila Chapter, Philadelphia, PA
11/5/06 Quality of Life: What Does it Mean for Those With ALS?
ALS Research Symposium and Reception, ALS Association DC/MD/VA Chapter, Washington, DC
1/10/07 Care for Patients with ALS Palliative Medicine Clinical Conference, Penn State University, Hershey, PA
3/6/07 Lou Gehrig’s Disease: More Than Just Weakness
Mini-Medical School, Penn State College of Medicine, Hershey, PA
4/13/07 ALS – It’s Not Just a Disorder of Motor Neurons
Department of Neurology Grand Rounds, Penn State University, Hershey, PA
4/27/07 Quality of life in ALS: What have we learned? Why are we studying this?
4th Annual ALS Research Symposium, Harrisburg, PA
12
4/27/07 Clinical trials past and present 4th Annual ALS Research Symposium, Harrisburg, PA
6/12/07 Language Syndromes and Lexical Access in ALS
2nd International Research Workshop on Frontotemporal Dementia in ALS, London, Ontario, Canada
6/16/07 Lou Gehrig’s Disease: An overview Living With ALS 2007 Symposium, Pittsburgh, PA
6/16/07 ALS Research Summary: Frontotemporal Dementia and Clinical Trials
Living With ALS 2007 Symposium, Pittsburgh, PA
9/28/07 Measuring Quality of Life in ALS: A Web-Based Initiative
6th Annual Meeting, North East ALS Consortium, Boston, MA
10/18/07 EDX Studies Generally are Helpful in the Evaluation of Patients with Weakness and Normal Neurological Examinations
54th Annual Meeting, American Association of Neuromuscular and Electrodiagnostic Medicine, Phoenix, AZ
1/24/08 Internet Based Quality of Life Assessment The ALS Association 2008 Annual Conference, Newport Beach, CA
1/25/08 Screening for Cognitive Dysfunction in Patients with ALS
The ALS Association 2008 Annual Conference, Newport Beach, CA
6/28/08 Clinical Management of ALS in the USA: A Model for the Care of Patients with Neurodegenerative Disorders
Symposium on Neurodegenerative Disorders, Tianjin, China
10/3/08 Validation of a Shorter ALS-Specific Quality of Life Instrument: The ALSSQOL-R
7th Annual Meeting, North East ALS Consortium, Boston, MA
10/4/08 ALS: Combining Clinical Care and Research to Benefit Patients
BrainTalk, Penn State Hershey Medical Center, Hershey, PA
1/16/09 ALS Update Department of Neurology Grand Rounds, Penn State University, Hershey, PA
4/26/09 Guillain-Barré Syndrome 61st Annual Meeting, American Academy of Neurology, Seattle, WA
10/16/09 Biomarkers in ALS: Keys to Diagnosis and Understanding
An Update on ALS Research, Philadelphia, PA
1/15/10 ALS Diagnosis and Symptom Management ALS Association Phila Chapter Teleconference
2/9/10 ALS Diagnosis and Symptom Management ALS Association National Teleconference
2/23/10 ALS Diagnosis and Symptom Management ALS Association National Teleconference
5/2/10 Quality of Life Research in ALS ALS Society of Canada Plenary Lecture , Toronto, Ontario, Canada
5/8/10 Quality of Life in ALS ALS Association, Wisconsin Chapter, Milwaukee,
13
WI
10/7/10 The Spinal Accessory Nerve and the Less Commonly Studied Nerves of the Limbs
American Association of Neuromuscular and Electrodiagnostic Medicine, Quebec City, Quebec, Canada
2/11/11 ALS: Assessing and Optimizing Quality of Life
Department of Neurology Grand Rounds, Penn State University, Hershey, PA
2/12/11 Supporting ALS Caregivers: Assessing Needs and Developing Interventions
MDA Regional Network ALS Conference, The Neurological Institute, Columbia University, New York, NY
5/26/11 ALS: Assessing and Optimizing Quality of Life
Department of Neurology, University of Edinburgh
9/16/11 Neuromuscular Vignettes American Association of Neuromuscular and Electrodiagnostic Medicine, San Francisco, CA
3/1/12 Diagnosis and Management of Acid Maltase Deficiency (Pompe Disease)
Lehigh Valley Hospital Neurology Conference, Allentown, PA
3/8/12 Quality of Life in ALS: What Does it Mean? Wadsworth Center, Albany, NY
3/9/12 Quality of Life in ALS: Assessing and Supporting Caregivers
Helen Hayes Hospital, West Haverstraw, NY
3/20/12 ALS (Lou Gehrig’s Disease): No Cure Yet, But Plenty of Hope
Mini-Medical School, Penn State Hershey Medical Center. Hershey, PA
Courses/Sessions Chaired
2007 Crossfire: Controversies in Neuromuscular and EDX Medicine. 54th Annual Meeting, American Association of Neuromuscular and Electrodiagnostic Medicine, Phoenix, AZ
2007 Palliative Care. 18th International Symposium on ALS/MND, Toronto, Ontario, Canada. 2008 Cognitive and Psychological Change. 19th International Symposium on ALS/MND,
Birmingham, England. 2010 Neuroanatomy for Nerve Conduction Studies. American Association of Neuromuscular and
Electrodiagnostic Medicine, Quebec City, Quebec, Canada
Participation in Expert Workgroups, Panel Discussions by Invitation 1995 Participant in Panel Discussion, ALS Pathogenesis and Treatment Conference, ALS Association,
Philadelphia, PA 1996 Participant in Panel Discussion, ALS Pathogenesis and Treatment Conference, ALS Association,
Philadelphia, PA 2000 Participant in meeting of ALS Peer Workgroup on Excellence in End-of-Life Care
14
2007 Speaker, Second International Research Workshop on Frontotemporal Dementia in ALS, London, Ontario, Canada
2010- Co-chair Cognitive/FTD subgroup, NINDS ALS Common Data Elements Working Group. 2011- Member, NINDS Common Data Elements Steering Committee
Data Safety Monitoring Board
2010- Chair, Data Safety Monitoring Board: A Phase I, Open-Label, First-in-Human, Feasibility and Safety Study of Human Spinal Cord derived Neural Stem Cell Transplantation for the Treatment of ALS
Other Professional Accomplishments
2007 Supervised, edited, and approved the production of a nerve conduction manual for our lab, to be used in training of technicians and physicians (residents and fellows), and to provide a compendium of the standard procedures used in our lab for performing nerve conduction studies.
2007 Supervised the purchase and installation of new software for the EMG lab which displays normal
values for nerve conduction studies as the studies are performed, and in the reports. The goal is to facilitate the adoption of uniform normal values by all physicians in the EMG lab, familiarize the technicians with normal values, facilitate the education of our physician trainees (residents and fellows), and facilitate communication with our referring physicians.
2007 Initiated monthly EMG Quality Assurance meetings which I supervise. 2010 Initiated Lumizyme therapy at Hershey Medical Center for patients with adult-onset Pompe
disease Funded Research Ongoing Research Support Biogen Idec, Inc 9/27/2012-9/30/2016 2% effort An open-label,multicenter extension study to evaluate the long-term safety and efficacy of dexpramipexole in subjects with amyotrophic lateral sclerosis Total award this site: $124,425 This is a multi-center study which is an open-label extension of a double-blind study of dexpramipexole for treatment of patients with ALS. Role: Principal investigator at Penn State Genzyme, Inc. 7/26/2012-7/31/2014 1% effort A phase 4 prospective exploratory muscle biopsy, biomarker, and imaging assessment study in patients with late-onset Pompe disease treated with alglucosidase alfa. Total award $42,592 This is a study of previously untreated patients with late-onset Pompe disease, utilizing muscle biopsies before and after treatment with alglucosidase alfa to assess glycogen clearance in muscle, characterizing
15
the disease burden with histologic and functional assessments, and exploring potential biomarkers in plasma and urine. Role: principal investigator at Penn State Genzyme, Inc. 6/28/2012-6/30/2022 0.5% effort Pompe registry Total award $151,500 This is an international registry of patients with Pompe disease. Our site will be entering data and as a result will have access to de-identified data entered by other sites for research purposes. Role: Principal investigator at Penn State Biogen Idec, Inc 4/25/2011-4/30/2014 2% effort A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of dexpramipexole in subjects with amyotrophic lateral sclerosis Total award this site: $264,574 This is a multi-center study comparing the effects of treatment with dexpramipexole to placebo for treatment of patients with ALS. Role: Principal investigator at Penn State Massachusetts General Hospital 1/1/2011-3/31/2013 2% effort Phase 2 selection trial of high dosage creatine and two dosages of tamoxifen in amyotrophic lateral sclerosis (ALS). Total award this site: $51,760 This is a multi-center study in which patients are randomized to high-dose creatine or one of two doses of tamoxifen for treatment of ALS. Role: Principal investigator at Penn State Massachusetts General Hospital 12/1/2007-2/28/2013 2% effort (no salary support) A Multicenter Study for the Validation of ALS Biomarkers Total award this site: $17,800 This is a multi-center study in which blood and cerebrospinal fluid will be collected from patients with ALS and with other neurological disorders for identification of potential biomarkers Role: Principal investigator at Penn State NIH, via Massachusetts General Hospital 12/1/2008-06/30/2013 2% effort Pharmacokinetics, Safety and Efficacy of Ceftriaxone in Patients with ALS (a multicenter study) Total award this site: Approximately $237,678 This is a double-blind, placebo-controlled, multicenter study of the efficacy of Ceftriaxone for the treatment of ALS. Role: Principal investigator at Penn State Jacobus Pharmaceuticals, Inc. 9/1/99 – ongoing Treatment of Congenital Myasthenia with 3,4-Diaminopyridine (3,4-DAP) Sponsor supplies investigational drug (compassionate use) Principal Investigator
16
Jacobus Pharmaceuticals, Inc 8/1/98 – ongoing Treatment of Lambert-Eaton Syndrome with 3,4-Diaminopyridine (3,4-DAP) Sponsor supplies investigational drug (compassionate use) Principal Investigator Ongoing Philanthropic Support Harriett and Paul Campbell Fund for ALS Research 10/4/04-ongoing at Penn State Milton S. Hershey Medical Center Ongoing support of ALS research $100,000 annually Zimmerman Family Love Fund 7/1/03-ongoing Support of ALS Research at Penn State College of Medicine/MS Hershey Medical Center $20,000 initial, plus approximately $10,000 annually ALS Association, Greater Philadelphia Chapter 2/1/03-ongoing Support of ALS research In excess of $100,000 annually Research Support Applications Pending Completed Research Support Cytokinetics 6/30/2011-6/30/2012 2% effort A phase II double-blind, randomized, placebo-controlled, study to evaluate the effects of multiple doses of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS) Total award this site: $55,421 This is a multi-center study of multiple doses over a 2 week period of a new compound designed to improve skeletal muscle strength and reduce fatigability in patients with amyotrophic lateral sclerosis by slowing the rate of calcium release from the troponin complex of skeletal muscle and thus sensitizing the contractile apparatus to calcium. Role: Principal investigator at Penn State Cytokinetics 2/25/2010-2/24/2012 2% effort A phase II double-blind, randomized, placebo-controlled, three-way crossover, pharmacokinetic and pharmacodynamic study of CK-2017357 in patients with amyotrophic lateral sclerosis Total award this site: $63,485 This is a multi-center study of a new compound designed to improve skeletal muscle strength and reduce fatigability in patients with amyotrophic lateral sclerosis by slowing the rate of calcium release from the troponin complex of skeletal muscle and thus sensitizing the contractile apparatus to calcium. Role: Principal investigator at Penn State Knopp Neurosciences Inc. 07/21/2009-01/19/2012 2% effort An Open-Label, Safety and Tolerability Study Evaluating KNS-760704 in Patients with Amyotrophic Lateral Sclerosis (ALS) – Protocol No. KNS-760704-CL211
17
Total award this site: $40,000 This is a multi-center open-label study of the safety and tolerability of this enantiomer of pramipexole for the treatment of ALS. It is the followup to a double-blind controlled study.
Role: Principal investigator at Penn State Greenwall Foundation 7/1/2009-12/31/2010 10% effort (no salary support) An Advance Care Planning Decision Aid for Patients with Amyotrophic Lateral Sclerosis Total award: $65,005 This is a study of a computer program to assist patients with ALS in developing advance directives, with the goals of determining whether the program improves knowledge and decision-making, and whether the process increases the medical team’s awareness of patients’ wishes.
Role: Co-Investigator (PI’s Michael Green, MD, MS and Benjamin H. Levi, MD, PhD) ALS Association 8/15/2009-8/14/2011 5% effort (no salary support) Development of Evidence-Based Practice Guidelines for Caregivers of Individuals with ALS and Cognitive Impairment: Pilot Study of an Educational Approach Total award: $10,250 This is a study to develop guidelines for use by caregivers of patients with ALS who have frontotemporal dementia
Role: co-Principal Investigator, with Claire Flaherty-Craig, PhD as the other co-PI The Judith & Jean Pape Adams Charitable Foundation 1/1/2010-12/31/2010 5% effort (no salary support) Impact of HFE H63D Allelic Variant on ALS Total award: $100,000 This is a collaborative effort with a basic science colleague to further explore the role of the hemochromatosis (HFE) gene in the etiopathogenesis of ALS.
Role: Co-Investigator (PI James Connor, PhD) The Judith & Jean Pape Adams Charitable Foundation 1/1/2009-12/31/2009 5% effort (no salary support) Impact of HFE H63D Allelic Variant on ALS Total award: $90,000 This is a collaborative effort with a basic science colleague to further explore the role of the hemochromatosis (HFE) gene in the etiopathogenesis of ALS.
Role: Co-Investigator (PI James Connor, PhD) Knopp Neurosciences Inc. 09/30/2008-12/31/2009 2% Effort A 2-Part, Randomized, Double-Blind, Safety and Tolerability Study Evaluating KNS-760704 in Patients with Amyotrophic Lateral Sclerosis (ALS) Total award this site: $82,130 This is a multi-center study of the safety and tolerability of this enantiomer of pramipexole for the treatment of ALS. If the study is successful, a larger efficacy study is planned.
Role: Principal investigator at Penn State Massachusetts General Hospital 9/1/2008-11/30/2009 1% effort
18
A Multicenter, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Lithium in combination with Riluzole in Volunteers with Amyotrophic Lateral Sclerosis (ALS) Total award at this site: $38,297 This is a double-blind placebo-controlled study of the efficacy of lithium plus riluzole for treatment of ALS.
Role: Co-Investigator at Penn State (PI Kevin Scott, MD) The ALS Association 2/1/2008-1/31/2009 5% effort (no salary support) The Role of HFE Polymorphisms in ALS Total award: $40,000 This is a collaborative effort with a basic science colleague to further explore the role of the hemochromatosis (HFE) gene in the etiopathogenesis of ALS. Role: Co PI (with James Connor, PhD) The Judith & Jean Pape Adams Charitable Foundation 1/1/2008-12/31/2008 5% effort (no salary support) The Role of HFE Gene Polymorphisms in ALS Total award: $140,779 This is a collaborative effort with a basic science colleague to further explore the role of the hemochromatosis (HFE) gene in the etiopathogenesis of ALS. Role: Co-Investigator (PI James Connor, PhD) NIH (R01 NS045087-01), Univ, of Kentucky 8/1/2004-11/30/2008 2% effort Early Treatment of ALS With Nutrition and NIPPV Total award: $183,445 ($129,649 direct costs) This is a multicenter study. The objectives of this proposal are: 1) to develop and validate strategies to improve tolerability of noninvasive positive pressure ventilation (NIPPV) in patients with ALS; 2) to identify factory that influence acceptance of this treatment modality; 3) to evaluate measures of early respiratory dysfunction in ALS; 4) to develop and validate methods to determine energy balance in ALS.
Role: Principal Investigator at Penn State University College of Medicine (Overall PI: Edward Kasarskis, M.D.)
CytRx Canceled by FDA and sponsor 2% effort A Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Investigate the Safety and Efficacy of Arimoclomol in Patients with Amyotrophic Lateral Sclerosis (ALS) Total award at this site: Approximately $121,000 (final amount to be determined) This is a double-blind, placebo-controlled, multicenter study of the efficacy of an inducer of heat-shock protein for the treatment of ALS. Role: Principal investigator at Penn State CytRx 1/31/2006-1/31/2007 2% effort A Multicenter , Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrphic
Lateral Sclerosis (ALS) – Open Label Extension Total award at this site: $26,550 ($19,923 direct costs) This is an open-label extension of a multicenter study to assess safety and tolerability of Arimoclomol for the treatment of patients with amyotrophic lateral sclerosis.
19
Role: Principal Investigator at Penn State University College of Medicine (Overall PI: Merit Cudkowicz, M.D.) CytRx 8/17/2005-8/16/2006 2% effort A Multicenter , Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrphic
Lateral Sclerosis (ALS) Total award at this site: $34,992 ($29,162 direct costs) This is a multicenter study to assess safety and tolerability of Arimoclomol for the treatment of patients with amyotrophic lateral sclerosis. Role: Principal Investigator at Penn State University College of Medicine (Overall PI: Merit Cudkowicz, M.D.) Muscular Dystrophy Association 7/1/2003-6/30/2006 5% effort (no salary support) Genotyping Analysis for Hfe Mutations in Amyotrophic Lateral Sclerosis $265,242 Co-Investigator (PI: James Connor, PhD) ALS Association 10/01/01-12/31/2003 2% effort (no salary support) Developing a Disease-Specific Tool to Assess Quality of Life in Amyotrophic Lateral Sclerosis $28,028 + Private Donations Principal Investigator Indiana University School of Medicine 9/1/98 – 12/31/05 A Registry of Arrhythmias in Myotonic Muscular Dystrophy Ongoing payment for costs incurred Principal Investigator at Penn State site Milton S. Hershey Neuromuscular Disease Research Support Grant 10/1/98-11/30/2005 Ongoing support of neuromuscular research at Penn State Milton S. Hershey Medical Center $15,000 annually Geisinger Clinic 3/1/2004-5/31/2005 Characterization of Sarcoglycan Mutations in Limb-Girdle Muscular Dystrophy (LGMD) Patients The objectives of this study are: 1) to screen limb-girdle muscular dystrophy patients for mutations in sarcoglycans in order to assess genotype-phenotype correlations; and 2) to identify patients or families who might potentially have mutations in novel genes that have not been characterized. Total amount of award: $8,419 Role: Principal Investigator at Penn State Site 2% effort ($5,080) Allergan, Inc. 2/28/2003-12/31/2004 Botulinum Toxin Injections to Decrease Sialorrhea in Patients with Amyotrophic Lateral Sclerosis : A Pilot Study Sponsor supplies botulinum toxin for study Principal Investigator
20
Advanced Respiratory, Inc. 2/19/2003-12/31/2004 Potential Clinical Efficacy of High Frequency Chest Wall Oscillation Administered Through Vest Device in Prolonging the Time Until Death or Tracheostomy in Patients with Amyotrophic Lateral Sclerosis Sponsor supplies high-frequency chest wall oscillation device Co-Investigator (PI: Robert Vender, MD) ALS Association 10/1/01 – 12/31/03 A Disease-Specific Tool to Assess Quality of Life in ALS $28,080 Principal Investigator Penn State Dean’s Feasibility Grant 7/1/2002-6/30/2003 Gene Profiling in ALS: A Targeted Assessment as a Diagnostic Tool and Means to Identify Novel Research Directions $30,000 Co-Investigator (PI: James Connor, PhD) ALS Association 7/1/00 – 9/30/01 Factors Which Affect Quality of Life in Caregivers of Patients with Amyotrophic Lateral Sclerosis $14,000 Principal Investigator ALS Association 2/1/99 – 1/31/00 Measuring the Quality of Life in Patients with ALS – A Pilot Study $18,000 Principal Investigator Abbot Laboratories 4/19/00 – 12/1/01 A Randomized, Double-Blind, Placebo-Controlled, Comparison of the Safety and Efficacy of the ABT-594 to Placebo in Subjects with Painful Diabetic Neuropathy $43,595 Principal Investigator R.W. Johnson Pharmaceutical Research Institute 12/9/00 – 12/1/01 A Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Evaluate the Efficacy and Safety of Topiramate Versus Placebo in the Relief of Pain in Diabetic Peripheral Neuropathy $45,719 Co-Investigator (PI: Milind Kothari, DO) Pro-Neuron, Inc 11/7/97 – 6/30/99 A Phase II, Multi-Center, Open Label, Clinical Trial to Assess the Safety and Efficacy of PN401 in Diabetic Neuropathy $60,000 Principal Investigator Pfizer, Inc 5/23/96 – 8/31/99
21
A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Effects of Oral Zopolrestat in Subjects with Peripheral Symmetrical Diabetic Polyneuropathy, Study #078-107-571 $360,673 Principal Investigator Cephalon, Inc 10/28/96 – 12/31/1999 A Treatment Protocol Using Myotrophin (human mescasermin [recombinant DNA origin]) Injections in Patients with Amyotrophic Lateral Sclerosis Sponsor supplied investigational drug (compassionate use) Principal Investigator Rhône-Poulenc Rorer Pharmaceuticals, Inc 9/14/95 – 3/15/96 Open-Label Trial of Rilutek (Riluzole) 50mg BID in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Sponsor supplied investigational drug prior to FDA approval (compassionate use) Principal Investigator Dean’s Feasibility Grant Program 6/1/94 – 5/31/95 Acetylcholine Receptor Induction Treatment in Myasthenia Gravis $24,988 Co-Investigator (PI: Erich Leith, PhD) Sandoz Pharmaceuticals 3/1/93 – 4/19/94 Randomized Double-Blind Placebo-Controlled Trial of Sandoglobulin in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) $30.888 Principal Investigator Organon, Inc 7/1/92 – 6/4/93 A Randomized Multicenter Double-Blind Placebo-Controlled Dose Finding/Efficacy/Safety Study of ORG 2766 in the Prevention or Amelioration of Vincristine-Induced Neuropathies in Patients with Hodgkin’s or Non-Hodgkin’s Lymphoma, Study No. 002.006 $66,558 Principal Investigator
22
PUBLICATIONS Articles in Peer-Reviewed Journals
1. Trumpower BL, Simmons Z. Diminished inhibition of succinate-cytochrome c reductase activity of resolved complex by thenoyltrifluoroacetone in the presence of antimycin. Biochem Biophys Res Comm 1978;82:289-295.
2. Trumpower BL, Simmons Z. Diminished inhibition of mitochondrial electron transfer from succinate to cytochrome c by thenoyltrifluoroacetone induced by antimycin. J Biol Chem 1979;254:4608-4616.
3. Lusby AF, Simmons Z, McGuire PM. Variation in mutagenicity of s-triazine compounds tested on four salmonella strains. Environ Mutagen 1979;1:287-290.
4. Biller J, Adams HP, Dunn V, Simmons Z, Jacoby CG. Dichotomy between clinical findings and MR abnormalities in pontine infarction. J Comput Assis Tomogr 1986;10:379-385.
5. Simmons Z, Biller J, Adams HP, Dunn V, Jacoby CG. Cerebellar infarction: Comparison of computed tomography and magnetic resonance imaging. Ann Neurol 1986;19:291-293.
6. Simmons Z, Biller J, Beck D, Keyes W. Painless compressive cervical myelopathy with false localizing sensory findings. Spine 1986;11:869-872.
8. Simmons Z, Bromberg MB, Feldman EL, Blaivas M. Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. Muscle Nerve 1993;16:77-83.
9. Bromberg MB, Forshew DA, Nau KL, Bromberg J, Simmons Z, Fries TJ. Motor unit number estimation, isometric strength, and electromyographic measures in amyotrophic lateral sclerosis. Muscle Nerve 1993;16:1213-1219.
10. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients without and with monoclonal gammopathy. Neurology 1993;43:2202-2209.
11. Simmons Z, Blaivas M, Aguilera AJ, Feldman EL, Bromberg MB, Towfighi J. Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. J Neurol Sci 1993;120:60-63.
12. Simmons Z, Wald J, Albers JW, Feldman EL. The natural history of a “benign” rib lesion in a patient with a demyelinating polyneuropathy and an unusual variant POEMS syndrome. Muscle Nerve 1994;17:1055-1059.
13. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995;118:359-368.
14. Doherty T, Simmons Z, O’Connell B, Felice KJ, Conwit R, Chan KM, Brown T, Stashuk DW, Brown WF. Methods for estimating the numbers of motor units in human muscles. J Clin Neurophys 1995;12:565-584.
15. Kluin KJ, Bromberg MB, Feldman EL, Simmons Z. Dysphagia in elderly men with myasthenia gravis. J Neurol Sci 1996;138:49-52.
23
16. Simmons Z, Tivakaran S. Acquired demyelinating polyneuropathy presenting as a pure clinical sensory syndrome. Muscle Nerve 1996;19:1174-1176.
17. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve 1997;20:1008-1015.
18. Thornton CA, Wymer JP, Simmons Z, McClain C, Moxley R. Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nature Genetics 1997;16:407-409.
19. Simmons Z, Nicholson T, Wilde C, Manders EK. Variation of calculated ulnar motor conduction velocity across the elbow with body mass index. Muscle Nerve 1997;20:1607-1608.
20. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve 1997;20:1569-1575.
21. Simmons Z, Thornton CA, Seltzer WK, Richards CS. Relative stability of a minimal CTG repeat expansion in a large kindred with myotonic dystrophy. Neurology 1998;79:1510-1511.
22. Kothari MJ, Blakeslee MA, Reichwein R, Simmons Z, Logigian EL. Are electrodiagnostic studies useful in clinical practice? Arch Phys Med Rehabilitation 1998;79:1510-1511.
23. Simmons Z. The use of skin biopsy in the study of small-fiber sensory neuropathies. Neurology Network Commentary 1998;2:283-287.
24. Simmons Z, Mahadeen ZI, Kothari MJ, Powers S, Wise S, Towfighi J. Localized hypertrophic neuropathy: magnetic resonance imaging findings and long-term clinical follow-up. Muscle Nerve 1999;22:28-36.
25. You H, Simmons Z, Freivalds A, Kothari MJ, Naidu SH. Relationships between clinical symptom severity scales and nerve conduction measures in carpal tunnel syndrome. Muscle Nerve 1999;22:497-501.
26. Simmons Z. Paraproteinemia and neuropathy. Curr Opin Neurol 1999;12:589-595.
28. Kothari MJ, Heistand M, Simmons Z. Side to side difference of nerve conduction amplitudes. Electromyogr Clin Neurophysiol 2000;40:81-82.
29. Simmons Z, Bremer BA, Robbins RA, Walsh SM, Fischer S. Quality of life in ALS depends on factors other than strength and physical function. Neurology 2000;55:388-392.
30. Simmons Z, Feldman EL. The pharmacologic treatment of painful diabetic neuropathy. Clinical Diabetes 2000;18:116-118.
31. Robbins RA, Simmons Z, Bremer BA, Walsh SM, Fischer S. Quality of Life in ALS is maintained as physical function declines. Neurology 2001;56:442-444.
32. Simmons Z, Epstein DK, Borg B, Mauger DT, Kothari MJ, Shefner JM. Reproducibility of motor unit number estimation in individual subjects. Muscle Nerve 2001 24:467-473.
33. Kovach MJ, Waggoner B, Leal SM, Gelber D, Khardori R, Levenstien MA, Shanks CA, Gregg G, Al-Lozi MT, Miller T, Rakowicz W, Lopate G, Florence J, Glosser G, Simmons Z, Morris JC, Whyte MP, Pestronk A, Kimonis VE. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique
24
dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab 2001;74:458-485.
34. Simmons Z, Towfighi J. Sporadic inclusion body myositis and hereditary inclusion body myopathy. J Clin Neuromusc Dis 2002;3:122-132.
35. Scott KR, Simmons Z, Boyer PJ. Hypothyroid myopathy with a strikingly elevated serum creatine kinase level. Muscle Nerve 2002;26:141-144.
36. Simmons Z, Feldman EL. Update on diabetic neuropathy. Curr Opin Neurol 2002;15:595-603. 37. Simmons Z, Peterlin BL, Boyer PJ, Towfighi J. Muscle biopsy in the evaluation of patients with modestly
elevated creatine kinase levels. Muscle Nerve 2003;27:242-244. 38. Walsh SM, Bremer BA, Felgoise SH, Simmons Z. Religiousness is related to quality of life in patients
with ALS. Neurology 2003;60:1527-1529. 39. Scott K, Simmons Z, Kothari MJ. A comparison of quantitative sensory testing to skin biopsy in small
fiber neuropathy. J Clin Neuromusc Dis 2003;4:129-132. 40. You H, Simmons Z, Freivalds A, Kothari MJ, Naidu SH, Young R. The development of risk assessment
models for carpal tunnel syndrome: a case-referent study. Ergonomics 2004;15:688-709. 41. Bremer BA, Simone A-L, Walsh S, Simmons Z, Felgoise SH. Factors Supporting Quality of Life Over
Time for Individuals with Amyotrophic Lateral Sclerosis: The Role of Positive Self- Perception and Religiosity, Ann Behav Med 2004;28:119-125.
42. Wang X, Lee S, Simmons Z, Boyer P, Scott K, Liu W, Connor J. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis. J Neurol Sci 2004;227:27-33.
43. Groh WJ, Lowe MR, Simmons Z, Bhakta D, Pascuzzi RM. Familial clustering of muscular and cardiac involvement in myotonic dystrophy type 1. Muscle Nerve 2005;31:719-724.
44. Simmons Z. Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death. Neurologist 2005;11:257-270.
45. Scott KR, Kothari MJ, Venkatesh YS, Murphy T, Simmons Z. Parotid gland injections of botulinum toxin A are effective in treating sialorrhea in amyotrophic lateral sclerosis. J Clin Neuromusc Dis 2005;7:62-65.
46. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, Sripathi N, Wortmann RL, Phillips PS. Genetic risk factors associated with lipid-lowering myopathies. Muscle Nerve 2006;34:153-162.
47. Chaisson CM, Walsh S, Simmons Z, Vender RL. A clinical pilot study: high frequency chest wall oscillation airway clearance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2006;7:107-111.
48. Fisher J, J, Darvish D, Simmons, Z. A case of hereditary inclusion body myopathy: one patient, two novel mutations. J Clin Neuromusc Dis 2006;7:179-184.
49. Simmons Z, Felgoise SH, Bremer BA, Walsh SM, Hufford DJ, Bromberg MB, David W, Forshew DA, Heiman-Patterson TD, Lai EC, McCluskey L. The ALSSQOL: balancing physical and non-physical factors in assessing quality of life in ALS. Neurology 2006;67:1659-1664.
50. Flaherty-Craig C, Eslinger P, Stephens B, Simmons Z. A rapid screening battery to identify frontal dysfunction in patients with ALS. Neurology 2006;67:2070-2072.
25
51. Wang, X-S, Simmons Z, Liu W, Boyer PJ, Connor JR. Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the postmortem cortex. Amyotroph Lateral Scler 2006;7:201-216.
52. Vender RL, Mauger D, Walsh S, Alam S, Simmons Z. Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival. Amyotroph Lateral Scler 2007;8:36-41.
53. Zimmerman E, Eslinger PJ, Simmons Z, Barrett AM. Emotional perception deficits in amyotrophic lateral sclerosis. Cogn Behav Neurol 2007;20:79-82.
54. Groh WJ, Lowe MR, Kincaid JC, Simmons Z, Ciafaloni E, Bhakta D, Nair GV, Marashdeh MM, Saha C, Zipes DP, Pascuzzi RM. Severity of electrocardiographic abnormalities and risk of sudden death in myotonic dystrophy type 1. N Engl J Med 2008;358:2688-2697.
55. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, Connor JR. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009;72:14-19.
56. Mitchell RM, Lee SY, Randazzo WT, Simmons Z, Connor JR. Influence of HFE variants and cellular iron on monocyte chemoattractant protein-I. J Neuroinflammation 2009;6:6 (19 Feb 2009).
57. Flaherty-Craig C, Brothers A, Dearman B, Eslinger P, Simmons Z. Penn State screen exam for the detection of frontal and temporal dysfunction syndromes: Application to ALS. Amyotroph Lateral Scler 2009;10:107-112.
58. Chio A, Schymick JC, Restagno G, Scholz SW, Lombardo F, Lai S-L, Mora G, Fung H-C, Britton A, Arepalli S, Gibbs JR, Nalls M, Berger S, Kwee LC, Oddone, EZ, Ding J, Crews C, Rafferty I, Washecka N, Hernandez D, Ferrucci L, Bandinelli S, Guralnik J, Macciardi F, Torri F, Lupoli S, Chanock SJ, Thomas G, Hunter DJ, Gieger C, Wichmann H-E, Calvo A, Mutani R, Battistini S, Giannini F, Caponnetto C, Mancardi GL, La Bella V, Valentino F, Monsurro MR, Tedeschi G, Marinou K, Sabatelli M, Conte A, Mandrioli J, Sola P, Salvi F, Bartolomei I, Siciliano G, Carlesi C, Orrell RW, Talbot K, Simmons Z, Connor J, Pioro EP, Dunkley T, Stephan DA, Kasperaviciute D, Fisher EM, Jabonka S, Sendtner M, Beck M, Bruijn L, Rothstein J, Schmidt S, Singleton A, Hardy J, Traynor BJ. A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum Mol Genet 2009;18:1524-1532.
59. Landsverk ML, Ruzzo EK, Mefford HC, Buysse K, Buchan JG, Eichler EE, Petty EM, Peterson EA, Knutzen DM, Barnett K, Farlow MR, Caress J, Parry GJ, Quan D, Gardner KL, Hong M, Simmons Z, Bird TD, Chance PF, Hannibal MC. Duplication within the SEPT9 gene associated with a founder effect in North American families with hereditary neuralgic amyotrophy. Hum Mol Genet 2009;18:1200-1208.
60. Murphy V, Felgoise SH, Walsh SM, Simmons, Z. Problem-solving skills predict quality of life and psychological morbidity in ALS caregivers. Amyotroph Lateral Scler 2009;10:147-153.
61. Simmons Z. Can we eliminate placebo in ALS clinical trials? Muscle Nerve 2009;39:861-865. 62. Felgoise SH, Stewart JL, Bremer BA, Walsh SM, Bromberg MB, Simmons Z. The SEIQoL-DW for
assessing quality of life in ALS: strengths and limitations. Amyotroph Lateral Scler 2009;10:456-462. 63. Ahmed A, Simmons Z. Electrodiagnostic Findings in a Patient with Waardenburg Syndrome. J Clin
Neuromusc Dis 2009;11:54-56.
26
64. Hall EC, Lee SY, Simmons Z, Neely EB, Nandar W, Connor JC. Prolyl-peptidyl isomerase, Pin1, phosphorylation is compromised in association with the expression of the HFE polymorphic allele, H63D. Biochimica et Biophysica Acta 2010;1802:389-395.
65. Sundaram A, Simmons Z, Towfighi J, Sheehan J, Reichwein R. Contralateral cranial polyneuropathy due to perineural invasion by a cutaneous squamous cell carcinoma. J Clin Neuromusc Dis 2010;11:132-136.
66. Simmons Z, Specht CS. The neuromuscular manifestations of amyloidosis. J Clin Neuromusc Dis 2010;11:145-157.
67. Mitchell RM, Simmons Z, Beard JL, Stephens HE, Connor J. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 2010;42:95-103.
68. Felgoise SH, Chakraborty BH, Bond E, Rodriguez J, Bremer BA, Walsh SM, Lai EC, McCluskey L, Simmons, S. Psychological morbidity in ALS: the importance of psychological assessment beyond depression alone. Amyotroph Lateral Scler 2010;11:351-358.
69. Liu Y, Lee SY, Neely E, Nandar W, Moyo M, Simmons Z, Connor JR. Mutant HFE H63D protein is associated with prolonged ER stress and increased neuronal vulnerability. J Biol Chem 2011;286:13161-13170.
70. Hossler C, Levi BH, Simmons Z, Green MJ. Advance care planning for patients with ALS: Feasibility of an interactive computer program. Amyotroph Lateral Scler 2011;12:172-177.
71. Flaherty-Craig CV, Brothers A, Yang C, Svoboda R, Simmons, Z. Declines in problem solving and anosognosia in ALS: application of Guilford’s structure of intellect theory. Cog Behav Neurol 2011;24:26-34.
72. Hall EC, Lee SY, Mairuae N, Simmons Z, Connor JR. Expression of the HFE allelic variant H63D in SH-SY5Y cells affects tau phosphorylation at serine residues. Neurobiol Aging 2011;32:1409-1419.
73. Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, Brannagain DO, Borasio GD, Hardiman O. Palliative care in amyotrophic lateral sclerosis – a review of current international guidelines and initiatives. J Neurol Neurosurg Psychiatry 2011;82:413-418.
74. Cupp J, Simmons Z, Berg A, Felgoise SH, Walsh SM, Stephens HE. Psychological health in patients with ALS is maintained as physical function declines. Amyotroph Lateral Scler 2011;12:290-296.
75. Mitchell RM, Lee SY, Simmons Z, Connor JR. HFE polymorphisms affect cellular glutamate regulation. Neurobiol Aging 2011 32:1114-1123.
76. Zamietra K, Lehman EB, Felgoise SH, Walsh SM, Stephens HE, Simmons, Z. Noninvasive ventilation and gastrostomy may not impact overall quality of life in patients with ALS. Amyotroph Lateral Scler 2012;13:55-58.
77. Burns TM, Graham CD, Rose MR, Simmons Z. Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle Nerve 2012;46:9-25.
78. Pagnini F, Simmons Z, Corbo M, Molinari E. Amyotrophic lateral sclerosis: time for research about psychological intervention? Amyotroph Lateral Scler 2012;13:416-417.
79. Flaherty-Craig C, Brothers A, McFalls A, Yang C, Simmons Z. VALUES: A national multicenter study of regional and gender differences in the FTD prodrome in ALS. Neurodegen Dis Manage (accepted for publication March 2012).
27
80. Houseman G, Walsh S, Brothers A, Lyter J, Simmons Z, Klapper J. Frontotemporal degeneration in the patient with ALS: helping the caregiver cope. J Neurosci Nurs (accepted for publication June 2012).
Peer Reviewed Articles On Line
1. Simmons, Z. Polio and infectious diseases of the anterior horn. www.uptodate.com
Letters, Book Reviews, Other Invited Reviews 1. Simmons Z, Bromberg MB, Feldman EL, Blaivas M. Polyneuropathy associated with IgA monoclonal
gammopathy of undetermined significance (a reply). Muscle Nerve 1993;16:1130. 2. Simmons Z. Book Review: Clinical Electromyography, Second Edition. Muscle Nerve 1994;17:356-357.
3. Simmons Z, Bremer BA, Walsh SM, Robbins RA. Quality of life in ALS is maintained as physical function declines (reply to letter). Neurology 2001;57:1939.
4. Simmons Z. Book Review: Clinical Evaluation and Diagnostic Tests for Neuromuscular Disorders. Muscle Nerve 2003;28:776.
5. Simmons Z. What’s in the Literature? J Clin Neuromusc Dis (Quarterly, beginning 2008)
Book Chapters 1. Feldman EL, Simmons Z. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Johnson RJ,
Griffin JW, eds. Current Therapy in Neurologic Disease. 4th ed. St. Louis: Mosby-Year Book, 1993:349-353.
2. Simmons Z. Case studies in peripheral neuropathy. In: Reichwein RK, Kothari MJ, eds. Hospital Physician Board Review Manual. Wayne PA: Turner White Communications, 2000:vol 5, part 3, 1-13.
3. Simmons Z, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy and related disorders. In: Katirji B, Kaminski H, Preston DC, Ruff RL, Shapiro BE, eds. Neuromuscular Disorders in Clinical Practice. Boston: Butterworth-Heinemann, 2002:567-588.
4. Boyer PJ, Simmons Z, Nifong TP. Cerebrospinal fluid. In: Lewandrowski K, ed. Clinical Chemistry: Laboratory Management and Clinical Correlations. Lippincott Williams & Wilkins, New York, 2002:877-891.
5. Simmons Z, Feldman EL. Treatment of diabetic neuropathy. In: Williams R, Wareham N, Kinmonth AL, Herman WH, eds. The Evidence Base for Diabetes Care. John Wiley & Sons, West Sussex, England 2002:555-576.
6. Simmons Z. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Bromberg MB, Smith AG, eds. Handbook of Peripheral Neuropathy. Taylor & Francis, Boca Raton, 2005:127-159.
7. Simmons, Z. Amyotrophic lateral sclerosis-like syndromes associated with malignancy. In: Gilman S, ed. Neurobiology of Disease. Elsevier, Amsterdam, 2007:513-519.
8. Simmons, Z. Management and Treatment of Autoimmune Neuropathies. In: Bertorini T, ed. Neuromuscular Disorders: Management and Therapy. Saunders/Elsevier, Philadelphia, 2011:215-235.
28
9. Simmons, Z. Rehabilitation of Motor Neuron Disease. In: Barnes M, Good D, eds. Neurorehabilitation. Handbook of Clinical Neurology (Michael Aminoff, series ed). Elsevier, Amsterdam (in press).
Abstracts
1. Trumpower BL, Simmons Z, Caughey JM, Lampson MC. Latent reconstitutive activity associated with succinate dehydrogenase in preparations of ubiquinone-cytochrome c reductase complex. Fed Proc 1978;37:1519.
2. Simons Z, Biller J, Adams HP, Dunn V, Jacoby CG. Cerebellar infarction: review of clinical findings and correlation with computed tomography and magnetic resonance imaging. Ann Neurol 1985;18:125.
3. Bromberg MB, Simmons Z, Forshew D, Nau K. Reproducibility of motor unit count estimation by the spike-triggered averaging technique. Muscle Nerve 1991;14:876.
4. Bromberg MB, Fries TJ, Tandan R, Simmons Z, Badger G, Nau K, Fillyaw MS. Relationships between motor unit counts and other electromyographic measures in amyotrophic lateral sclerosis. Muscle Nerve 1991;14:876.
5. Simmons Z, Blaivas M, Bromberg MB, Feldman EL. Polyneuropathy associated with IgA monoclonal gammopathy. Muscle Nerve 1991;14:907.
6. Kluin KJ, Bromberg MB, Feldman EL, Simmons Z. Dysphagia in elderly men with myasthenia gravis (MG). Neurology 1992; 42 (suppl 3):232.
7. Simmons Z, Felman EL, Pestronk A. Heterogeneity in polyneuropathy associated with elevated anti-MAG titers with and without IgA monoclonal gammopathy. Neurology 1992;42 (suppl 3):333.
8. Simmons Z, Wald J, Albers JW, Feldman EL. Polyneuropathy in POEMS syndrome with a “benign” rib lesion. Muscle Nerve 1993;16:1105.
9. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, both without and with monoclonal gammopathy. Peripheral Nerve Society, June 12-16, 1994.
10. Simmons Z, Stashuk D, Brown WF. Motor unit estimation using an automated F-response technique: reproducibility of results. Muscle Nerve 1994;17:1120.
11. Tivakaran SC, Simmons Z, Towfighi J. Muscle biopsy as a diagnostic tool in patients with prolonged weakness after neuromuscular blockers and high-dose corticosteroids. Muscle Nerve 1994;17:1123.
12. Wald JJ, Albers JW, Simmons Z, Roberts JA, Capo B. Cisplatin neuropathy: clinical and nerve conduction correlation. Muscle Nerve 1994;17:1116.
13. Wald JJ, Albers JW, Simmons Z, Roberts JA, Capo B. Cisplatin neuropathy not prevented by ACTH (4-9) Analog. Neurology 1995;45 (suppl 4):A170.
14. Simmons Z, Tivakaran S. “Sensory neuropathy” with more generalized electrodiagnostic abnormalities. Muscle Nerve 1995;18:1054-1055.
16. Simmons Z, Thornton CA. Relative stability of a minimal CTG repeat expansion in a large kindred with myotonic dystrophy. Ann Neurol 1995;38:303-304.
29
17. Simmons Z. Chronic inflammatory demyelinating polyneuropathy and optic neuritis in a patient with thymoma and multiple autoantibodies. Muscle Nerve 1996;19:1225.
18. Blakeslee MA, Simmons Z, Longigian EL, Kothari MJ. Does an electrodiagnostic study change clinical management? Muscle Nerve 1996;19:1225.
20. O’Connell BK, Simmons Z, Tatarian GT. Treatment of jaw spasm in ALS with botulinum toxin. Neurology 1997;48:A128.
21. Stabley J, Simmons Z, Kothari MJ. Axonal polyradiculoneuropathy associated with infectious mononucleosis. Muscle Nerve 1997;20:1057.
22. Mahadeen ZI, Simmons Z, Kothari MJ, Powers S, Wise S, Towfighi J. Localized hypertrophic neuropathy: magnetic resonance imaging findings and long-term follow up. Muscle Nerve 1997;20:1062.
23. Kothari MJ, Heistand M, Simmons Z. Side-to-side comparison of amplitudes in nerve conduction studies. Muscle Nerve 1997;20:1081.
24. Alvarez RB, Simmons Z, Engel WK, Askanas V. New autosomal-dominant inclusion-body myopathy (AD-IBM) with many congophilic muscle nuclei that contain paired-helical filaments (PHFs) composed of phosphorylated tau. Neurology 1998;50:A204.
25. Simmons Z, Bremer BA, Walsh SM, Green MJ. Measuring quality of life in patients with ALS: a pilot study. Neurology 1999;52 (suppl 2):A527-528.
26. Alvarez RB, Simmons Z, Heller SL, Broccolini A, Engel WK, Askanas V. Studies of apoptosis in muscle biopsies of autosomal-dominant inclusion-body myopathy. Neurology 1999;52 (suppl 2):A333-A334.
27. Sue CM, Guo FL, Tanji K, Shanske S, Simmons Z, Bonilla E, DiMauro S. Limb girdle myopathy and respiratory insufficiency is associated with the A3302G mutation in the tRNALeu(UUR) Gene. Ann Neurol 1999;46:462.
28. Simmons Z, Bremer BA, Robbins RA, Walsh SM, Fischer S. Measuring quality of life in patients with amyotrophic lateral sclerosis: Validation of instruments. Neurology 2000;54(suppl 3):A343.
29. Murphy-Reiley VB, Simmons Z, Walsh SM, Robbins RA, Felgoise SH, Murphy TH, Bremer BA. Factors that predict quality of life and psychological morbidity in caregivers of patients with amyotrophic lateral sclerosis: a pilot study. Neurology 2001;56(suppl 3):A200-A201.
30. Bremer BA, Walsh S, Robbins R, Simmons Z. Religious participation and quality of life for individuals with amyotrophic lateral sclerosis. Ann Behav Med 2001;23(suppl):S124.
31. Yaney G. Ferrante RJ, Simmons Z, Dellinger B, Boyer PJ. Skeletal muscle pathology in the G93A mousse model of amyotrophic lateral sclerosis: an early marker of disease progression. Muscle Nerve 2001;24:1427-1428.
32. Bremer BA, Walsh SM, Felgoise SH, Simmons Z. Increasing importance of religiosity with the progression of amyotrophic lateral sclerosis. ALS 2001;2(suppl 2):49-50.
33. Felgoise SH, Bremer BA, Walsh S, Allen JS, Simmons Z. Development and validation of a quality of life scale specific for amyotrophic lateral sclerosis. Presented at the 36th Annual Convention of the Association for Advancement of Behavior Therapy, Reno, Nevada, November 14-17, 2002.
30
34. Felgoise SH, Allen JS, Bremer BA, Walsh S, Simmons Z. Quality of life assessment: further evaluation of the SEIQoL-DW as a useful tool with amyotrophic lateral sclerosis (ALS). Presented at the 37th Annual Convention of the Association for Advancement of Behavior Therapy, Boston, MA, November 2003.
35. Bremer BA, Simone AL, Walsh S, Simmons Z, Felgoise SH. Religion and quality of life with amyotrophic lateral sclerosis. Presented at the 2nd Annual Mid-Winter Research Conference on Religion and Spirituality, Columbia, MD, March 2004.
36. Flaherty-Craig C, Simmons Z. Deficient social judgment in non-bulbar amyotrophic lateral sclerosis. Neurology 2004;62(suppl 5):A323-A324.
37. Scott KR, Kothari MJ, Simmons Z, Murphy TH, Venkatesh YS. Parotid gland injections of botulinum A toxin for refractory sialorrhea in patients with amyotrophic lateral sclerosis – a pilot study. Neurology 2004;62(suppl 5):A136.
38. Hegde MR, Chan YM, Chong B, Khadilkar SV, Shi W, Farber M, Wong V, IP P, Simmons Z, Richards CS, Love, DR. Biological and Clinical Consequences of Sarcoglycan Gene Mutations. Presented at the Annual Meeting of the American Society of Human Genetics, Toronto, Ontario, Canada, October 26-30, 2004.
39. Simmons Z. Key determinants of quality of life in ALS. ALS 2004;5(suppl 2):21. 40. Wang XS, Lee SY, Simmons Z, Boyer P, Scott K, Liu W, Connor JR. Increased incidence of HFE
mutations in amyotrophic lateral sclerosis. ALS 2004;5(suppl 2):38. 41. Wang XS, Liu W, Boyer P, Simmons Z, Connor JR. Increased incidence of HFE mutations in
amyotrophic lateral sclerosis. ALS 2004;5(suppl 2):40. 42. Flaherty-Craig C, Simmons Z. Deficient social judgment in non-bulbar amyotrophic lateral sclerosis.
ALS 2004;5(suppl 2):52. 43. Simmons Z, Felgoise SH, Bremer BA, Walsh SM, Bromberg MB, David W, Forshew DA, Herman-
Patterson TD, Lai E, McCluskey L. Development and validation of an ALS-specific quality of life instrument. ALS 2004;5(suppl 2):140.
44. Zimmerman EK, Eslinger PJ, Muniz KJ, Jackson H, Simmons Z, Barrett AM. Emotional perceptual deficit in persons with amyotrophic lateral sclerosis. Journal of the International Neuropsychological Society 2004; 10(Suppl 1).
45. Flaherty-Craig CV, Simmons Z. Deficient social judgment in amyotrophic lateral sclerosis. Neurology. 2005;64(suppl 1):A372.
46. Lee S, Simmons Z, Wang X, Connor J. SOD1 down-regulation in ALS patients carrying an Hfe mutation. ALS 2005;6(suppl 1):84-85.
47. Scott KR, Bigler D, Meadowcroft M, Stephens H, Yang Q, and Simmons Z. A Novel MRI Technique Demonstrates Thinning of Primary Motor Cortex in ALS. Neurology 2006;66(suppl 2):A245.
48. Meadowcroft MD, Bigler DC, Simmons Z, Smith MB, Yang QX. Quantitative magnetic resonance and histological analysis of primary motor neuronal loss in ALS. Neurology 2006;66(suppl 2):A245.
49. Flaherty-Craig CV, Walgren A, Simmons Z, Kothari M. Disruptions in cognition and personality in adult-onset myotonic dystrophy type 1. Neurology 2006;66(suppl 2):A151
31
50. Bigler DC, Scott KR, Meadowcroft MD, Wang JX, Stephens HE, Simmons Z, Yang QX, Smith MB. Gray matter thinning demonstrated in ALS using novel thickness maps. Proc Intl Soc Mag Reson Med 2006;14: 728.
51. Flaherty-Craig CV, Wohlgren A, Kothari, M, Simmons, Z: Cognitive and personality profile of Adult-onset Myotonic Dystrophy Type-1. Accepted for platform presentation, International Neuropsychological Society Meeting, Zurich, Switzerland, July, 2006.
52. Flaherty-Craig C, Pinnelli SJ, Eslinger P, Simmons Z. Deficient lexical access in ALS is associated with poor divergent production and social intelligence. Amyotrophic Lateral Scler 2006;7(suppl 1):94-95.
53. Cudkowicz M, Shefner J, Simpson E, Grasso D, Sherman A, Yu H, Opoliner A, Balakrishna S, Schoenfeld D, Zhang H, Finkelstein D, Taft J, Watson M, Dibernardo A, Pulley D, Verma A, Koggan D, Steele J, Bedlack R, Grace K, Heiman-Patterson T, Barr C, Barohn R, Walsh M, Herbelin L, Simmons Z, Stephens H, Ensrud E, Zimmerman M, David W, Conn S, Mozaffar T, Martin V, Hung J, Milan D, Wieland S, Barber J, Brown R. A multicenter, dose ranging safety and pharmacokinetics study of Arimoclomol in ALS. Amyotrophic Lateral Scler 2006;7(suppl 1):113.
54. Bremer BA, Walsh S, Gascho B, Hairston P, Simmons Z. Pastoral interventions that work: perspectives of individuals with amyotrophic lateral sclerosis. Ann Behav Med 2007;33 (suppl):S031.
55. Stephens HE, Felgoise SH, Bremer BA, Walsh SM, Simmons Z. An ALS-specific tool to measure quality of life. Presented at the Regional Symposium on Health Care and Quality of Life, Penn State Harrisburg, March 2, 2007.
56. Flaherty-Craig C, Brothers A, Simmons Z. Deficient lexical access in ALS is associated with poor divergent production and social intelligence. Neurology 2007;68(suppl 1):A12.
57. Mitchell RM, Lee Sang Y, Stephens HE, Simmons Z, Connor JR. The relevance of a hemochromatosis gene mutation in ALS. Neurology 2007;68(suppl 1):A246.
58. Duff J, Felgoise SH, DiTomasso RA, Simmons Z. Oral Communication Ability and Quality of Life in Persons with Amyotrophic Lateral Sclerosis. Presented at the 41st annual meeting of the Association for Behavioral and Cognitive Therapies, Philadelphia, PA, November 15-18, 2007.
59. Connor JR, Mitchell RM, Lee SY, Stephens HE, Simmons Z. Biomarkers in ALS patients stratified by HFE genotype. Society for Neuroscience 2007. 489.11/Z8.
60. Felgoise SH, Rodriguez JL, Bremer BA, Walsh SM, Stephens HE, Horowitz MD, Simmons Z. Validation of the ALS specific quality of life-revised measure (ALSSQOL-R). Presented at the 18th International Symposium on ALS/MND, Toronto, Ontario, Canada, December 1-3, 2007.
61. Flaherty-Craig C, Eslinger P, Brothers A, Dearman B, Simmons, Z. A cognitive screen of frontal dysfunction in ALS with differentiation of subtypes. Amyotroph Lateral Scler 2007;8:101-102.
62. Stephens HE, Green B, Bremer B, Felgoise S, Walsh S, Simmons Z. A pilot study to evaluate the reliability of administering the ALS-specific quality of life instrument-revised (ALSSQOL-R) in a self-administered format vs. interview based format. Amyotroph Lateral Scler 2007;8:103-104.
63. Mitchell R, Lee S, Mauger D, Stephens H, Simmons Z, Connor J. Biomarkers in ALS patients stratified by HFE genotype. Amyotroph Lateral Scler 2007;8:120.
64. Mitchell R, Lee S, Simmons Z, Connor J. Impact of HFE polymorphisms on cellular glutamate regulation. Amyotroph Lateral Scler 2007;8:178.
32
65. Karsarskis E, Mendiondo M, Xu A, Stockberger S, Simmons Z, Mitsumoto H, Tandan R, Bromberg M, Healey M, ALS Nutrition/NIPPV Research Group. Use of accelerometers to measure disease progression in ALS. Amyotroph Lateral Scler 2007;8:61.
66. Tandan R, Bromberg MB, Kasarskis EJ, Mitsumoto HM, Simmons Z, Matthews DB. Water turnover in ALS measured by the doubly labeled water method. Neurology 2008;70(suppl 1):A138.
67. Mitchell RM, Randazzo WT, Freeman WM, Stephens HE, Simmons Z, Connor JR. CSF biomarkers can identify ALS patients and reveal influences of HFE polymorphisms. Neurology 2008;70(suppl 1):A238.
68. Stephens HE, Walsh SM, Simmons Z. A national survey of quality of life for ALS patients in the United States. Amyotroph Lateral Scler 2008;9(suppl 1):12.
69. Felgoise S, Rodriguez J, Stephens H, Walsh S, Bremer B, Simmons Z. Validation of a shorter ALS-specific quality of life instrument: the ALSSQOL-R. Amyotroph Lateral Scler 2008;9(suppl 1):12-13.
70. Flaherty-Craig C, Brothers A, Dearman B, Eslinger P, Simmons Z. Rapid screen exam for the detection of frontal and temporal dysfunction syndromes: application to ALS. Amyotroph Lateral Scler 2008;9(suppl 1):35.
71. Wiley N, Mitchell R, Madhankumar A, Simmons Z, Connor J. Targeted liposomes for treatment of ALS in mutant SOD1 mouse model. Amyotroph Lateral Scler 2008;9(suppl 1):63.
72. Mitchell R, Traynor B, Stephens H, Simmons Z, Connor J. Association of the H63D allele with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008;9(suppl 1):103-104.
73. Stayer CJ, Bremer BA, Green BL, Brothers A, Brussock C, D’Angelo T, Felgoise SH, Gascho B, Hill S, Lyter J, Paul Z, Rodriguez J, Stephens HE, Walsh S, Yates J, Young J, Simmons Z. Development of Evidence-Based Standards of Care for Optimizing the Quality of Life of Caregivers of Individuals with Amyotrophic Lateral Sclerosis: A Systematic Review of the Literature. Presented at the Society of Behavioral Medicine 30th annual meeting, Montreal, Canada, April 22-25, 2009.
74. Bigler DC, Aksu Y, Stephens HE, Vesek J, Scott KR, Flaherty-Craig C, Wang J, Eslinger PJ, Simmons Z, Yang QX. High-resolution Longitudinal Voxel-Based Morphometric Study in ALS. Proc. Intl. Soc. Mag. Reson. Med. 17 (2009).
75. Lowden MR, Stephens HE, Simmons Z, Scott KR. Moderate Intensity Resistance Training Does Not Significantly Alter Disease Progression in a Representative Group of ALS Patients. Neurology 2009;72(suppl 3):A361.
76. Stephens HE, Walsh S, Bremer B, Simmons Z. Caring for the caregiver part 1: using evidence-based practice to design interventions to support ALS caregivers. Amyotroph Lateral Scler 2009;10(suppl 1):14.
77. Stephens HE, Walsh S, Bremer B, Simmons Z. Caring for the caregiver part 2: evaluation of an ALS caregiver assessment form for a multidisciplinary ALS clinic. Amyotroph Lateral Scler 2009;10(suppl 1):199.
78. Mitchell R, Lee S, Nandar W, Neely E, Simmons Z, Connor J. HFE polymorphisms affect glutamate regulation. Amyotroph Lateral Scler 2009;10(suppl 1):22.
79. Liu Y, Lee S, Mitchell R, Simmons Z, Connor J. Cellular impact of HFE H63D Allelic variant on ALS. Amyotroph Lateral Scler 2009;10(suppl 1):21.
80. Mitchell R, Simmons Z, Connor J. Validation of a CSF biomarker panel for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10(suppl 1):15.
33
81. Flaherty-Craig C, Brothers A Simmons Z. Validation of the Penn State brief exam of frontal and temporal dysfunction syndromes in amyotrophic lateral sclerosis: application of Guilford’s structure of intellect theory. Amyotroph Lateral Scler 2009;10(suppl 1):44.
82. Wiley N, Mitchell R, Madhankumar AB, Simmons Z, Connor J. Potential nanotechnology platform for ALS efficacy in the mSOD1G93A mouse model. Amyotroph Lateral Scler 2009;10(suppl 1):81.
83. Hall E, Lee S, Simmons Z, Connor J. HFE polymorphisms and ALS: insights into a putative risk factor via tau phosphorylation mechanisms. Amyotroph Lateral Scler 2009;10(suppl 1):113.
84. Simmons Z, Felgoise SH, Rodriguez JL, Walsh SM, Bremer BA, Stephens HE. Validation of a shorter ALS-specific quality of life instrument: the ALSSQOL-R. Neurology 2010;74 (suppl 2):A177-A178.
86. Connor JR, Mitchell RM, Simmons Z. Cerebrospinal fluid biomarkers panel in amyotrophic lateral sclerosis. Neurology 2010;74 (suppl 2):A201.
87. Evans J, Specht C, Simmons Z. Pathological findings in a case of familial amyloidosis, Thr60Ala (Appalachian-type), with prominent peripheral neuropathy. J Neuropathol Exp Neurol 2010;69:556.
88. Rodriguez JL, Felgoise SF, Simmons Z. The Relationship between Physical Functioning and the Experience, Desire, and Satisfaction of Physical, Emotional, and Social Intimacies in Persons with ALS. Poster presented at Philadelphia Behavior Therapy Association Student Poster Exhibition. May 2010.
89. Bigler DC, Flaherty-Craig C, Aksu Y, Lee B-Y, Scott KR, Stephens HE, Vesek JJ, Wang J, Shaffer ML, Eslinger PJ, Simmons Z, Yang QX. Cross-sectional and longitudinal voxel-based relaxometry study in ALS. Proc Intl Soc Mag Reson Med 2010;18:1968.
90. Brothers A, Green MJ, Levi B, Farace E, Simmons Z. An advance-care planning decision aid for patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11(suppl 1):14.
91. Young J, Felgoise S, Stephens HE, Walsh S, Simmons Z. A national study of amyotrophic lateral sclerosis multidisciplinary clinic utilization. Amyotroph Lateral Scler 2010;11(suppl 1):18-19.
92. Liu Y, Lee S, Neely E, Nandar W, Simmons Z, Connor J. Mutant HFE H63D protein is associated with prolonged ER stress and decreased neuronal viability in ALS. Amyotroph Lateral Scler 2010;11(suppl 1):22.
93. Brothers A, Walsh S, Lyter J, Houseman G, Klapper J, Simmons Z. Identifying the needs of the ALS/FTD caregiver: development, implementation, and evaluation of a clinical assessment instrument. Amyotroph Lateral Scler 2010;11(suppl 1):49-50.
94. Bremer B, Stephens HE, Walsh S, Felgoise S, Simmons Z. Identifying needs and interventions to support caregivers of patients with ALS. Amyotroph Lateral Scler 2010;11(suppl 1):50.
95. Nandar W, Neely E, Simmons Z, Connor J. The H63D HFE gene variant reduces survival and disease duration in SODG93A mice. Amyotroph Lateral Scler 2010;11(suppl 1):54.
96. Kasarskis E, Mendiondo M, Kryscio R, Tandan R, Potter C, Matthews D, Mitsumoto H, Simmons Z, Bromberg M, Wells S, Healey M, The ALS Nutrition/NIPPV Study Group. Predicting energy needs in ALS: results of the ALS nutrition/NIPPV study. Amyotroph Lateral Scler 2010;11(suppl 1):56.
34
97. Ali-Rahmani F, Lee S, Nandar W, Neely B, Simmons Z, Connor J, Schengrund C-L. H63D variant of HFE alters cholesterol metabolism: a potential mechanism for disruption of cell signaling in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11(suppl 1):79.
98. Liu Y, Simmons Z, Connor J. HFE H63D contributes to increased TDP-43 level and cytosolic localization. Amyotroph Lateral Scler 2010;11(suppl 1):109.
99. Pagnini F, Simmons Z, Felgoise S, Lunetta C, Corbo M. Italian validation of amyotrophic lateral sclerosis specific quality of life-revised (ALSSQOL-R): a comparison between US and Italian samples. Amyotroph Lateral Scler 2010;11(suppl 1):126-127.
100. Flaherty-Craig C, Brothers A, Svoboda R, Simmons Z. Impaired insight for cognitive decline in ALS with cognitive impairment. Amyotroph Lateral Scler 2010;11(suppl 1):146.
101. Shefner J, Cudkowicz M, Maragakis N, Miller R, Wolff A, Lee J, Saikali K, Chen M, Bradshaw D, Levine T, Katz J, Heiman-Patterson T, Kasarskis E, Rosenfeld J, Simmons Z, Boylan K, Bedlack R, Pestronk A, Goslin K, Atassi N, Jackson C, Watson ML, Shaver K, Simpson E, NEALS Consortium. A phase 2, single dose study of CK-2017357, a skeletal muscle troponin activator in patients with ALS. Neurology 2010;76(suppl 4):A666.
102. Bremer BA, Stephens HE, Walsh S, Hinkle S, Felgoise S, Simmons Z. Identifying needs and interventions to support caregivers of patients with ALS (presented at the 7th Annual ALS/MND Nursing Symposium, Chicago, October 21-23, 2011.
103. Stephens HE, Walsh S, Felgoise S, Simmons Z. Quality of life assessment: methods and application (presented at the 7th Annual ALS/MND Nursing Symposium, Chicago, October 21-23, 2011.
104. Brothers A, Walsh S, Lyter J, Houseman G, Klapper J, Simmons Z. Identifying the needs of the ALS/FTD caregiver (presented at the 7th Annual ALS/MND Nursing Symposium, Chicago, October 21-23, 2011.
105. Flaherty-Craig C, Brothers A, Simmons Z. A national study for the characterization of emerging cognitive and behavioral decline. Amyotroph Lateral Scler 2011;12(suppl 1):79.
106. Shefner J, Brooks BR, Simmons Z, Mitsumoto H, Wolff AA, Lee JH, Jones DS, Mao J, Meng L, Cedarbaum JM for the CY 4024 Investigator Group. A study to evaluate safety, tolerability and clinical outcomes following repeated doses of CK-2017357 (CK-357) in patients with amyotrophic lateral sclerosis (presented at the International ALS/MND Symposium, Sydney, Australia, Nov 30-Dec 2, 2011.
107. Shefner JM, Barohn R, Boylan K, Bradshaw D, Brooks B, Heiman-Patterson T, Katz J, Maragakis N, Mitsumoto H, Pestronk A, Watson ML, Simmons Z, Cedarbaum J, Chen MM, Lee J, Masonek j, Meng L, Wolff A, and the NEALS Consortium, A Study To Evaluate Safety and Tolerability of Repeated Doses of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis. Neurology 2012;78 (Meeting Abstracts):S25.005.
